vimarsana.com
Home
Live Updates
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugens Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers -January 30, 2024 at 08:06 am EST : vimarsana.com
MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers -January 30, 2024 at 08:06 am EST
Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancersROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 --...
Related Keywords
United Kingdom ,
Mary Jane Elliott ,
Mark Lewis ,
Panmure Gordon ,
David Deuchler ,
Chris Welsh ,
Rupert Dearden ,
Kumar Srinivasan ,
Maher Masoud ,
Emma Earl Freddy Crossley ,
Christine Fanelle ,
Nasdaq ,
Maxcyte Inc ,
Drug Administration ,
Linkedin ,
Twitter ,
Wugen Inc ,
Gilmartin Group ,
Flow Electroporation ,
Orphan Drug ,
Fast Track ,
Rare Pediatric Disease Designations ,
Cyte Contacts ,
Joint Corporate ,
Markets ,
vimarsana.com © 2020. All Rights Reserved.